Endpoints News
Anthropic enters preclinical R&D Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
1 July, 2026
news
A June flourish lifts biotech megaround tally in first half of 2026
ENDPOINTS NEWS
Ipsen to scoop up Memo Therapeutics and its kidney infection drug
ENDPOINTS NEWS
Updated: Anthropic launches Claude Science as a product for biopharma, starts own drug programs
ENDPOINTS NEWS
Endpoints webinars
Jul 30
1:00 pm ET
Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights
GUARDANT
Manufacturing Day 2026
Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.
PHARMA
FDA's acting director of cell and gene therapies to leave position
ENDPOINTS NEWS
FDA taps Lilly, Fujifilm and five more for its factory-speeding PreCheck pilot
ENDPOINTS NEWS
AbbVie and Genmab's latest win brings Epkinly closer to label expansion
ENDPOINTS NEWS
FDA reviewers oppose allowing seven peptides for compounding
ENDPOINTS NEWS
Unicycive gets second CRL for kidney drug as manufacturing woes continue
ENDPOINTS NEWS
in case you missed it
1.
Exclusive: House China panel questions Bristol Myers, Pfizer on trial sites
ENDPOINTS NEWS
2.
Abivax aims to set cancer concerns with ulcerative colitis drug to rest
ENDPOINTS NEWS
3.
NEJM retracts pivotal data for Amgen's Tavneos
ENDPOINTS NEWS
4.
News Briefing
Sarepta's FDA decision date; Flare gets Anna Protopapas as CEO
ENDPOINTS NEWS
5.
Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myers
ENDPOINTS NEWS
6.
BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study
ENDPOINTS NEWS
7.
Sanofi’s Pompe disease treatment successor passes Phase 3 test in babies
ENDPOINTS NEWS
8.
Healthcare personnel and external vendors affected by Novo cyberattack
MedWatch
Reynald Castaneda
.

At the same event Anthropic unveiled Claude Science, the AI company said it was also developing preclinical drug candidates. Details are sparse, but it noted the work would be on "neglected" diseases and its purpose was to get ground-level experience in drug research. We can't wait to see how this turns out.

.
Reynald Castaneda
Deputy Editor, Endpoints News
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin